HOME | LOGIN | JOIN US  
APJCP APJCP Submission APOCP APOCP Documents  
Search 
 
   
About the APJCP 
 Information for Authors
 APJCP Issues 
VOLUME 16, 2015  Issue Number 18 , 8253-8258
DownLoad : 8253-8258 8.31 Shigeki Takemoto-Revised.pdf
RESEARCH ARTICLE
Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study
Shigeki Takemoto et al
Abstract
Elevated levels of soluble CD30 (sCD30) are linked with various T-cell neoplasms. However, the relationship between sCD30 levels and the development of adult T-cell leukemia (ATL) in human T-cell leukemia virus type 1 (HTLV-1) carriers remains to be clarified. We here investigated whether plasma sCD30 is associated with risk of ATL in a nested case-control study within a cohort of HTLV-1 carriers. We compared sCD30 levels between 11 cases (i.e., HTLV-1 carriers who later progressed to ATL) and 22 age-, sex- and institution-matched control HTLV-1 carriers (i.e., those with no progression). The sCD30 concentration at baseline was significantly higher in cases than in controls (median 65.8, range 27.2-134.5 U/mL vs. median 22.2, range 8.4-63.1 U/mL, P=0.001). In the univariate logistic regression analysis, a higher sCD30 (¡Ã30.2 U/mL) was significantly associated with ATL development (odds ratio 7.88 and the 95% confidence intervals 1.35–45.8, P = 0.02). Among cases, sCD30 concentration tended to increase at the time of diagnosis of aggressive-type ATL, but the concentration was stable in those developing the smoldering-type. This suggests that sCD30 may serve as a predictive marker for the onset of aggressive-type ATL in HTLV-1 carriers.
Key Words: Adult T-cell leukemia (ATL) - CD30 - human T-cell leukemia virus type 1 (HTLV-1)
 
APJCP Editorial Office : National Cancer Center, Korea. Tel : +82-31-920-1938 Fax : +82-31-920-1939
E-mail : apjcpedit@gmail.com
323 Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, 410-769, Republic of Korea
Copyright ¨Ï National Cancer Center, Korea. All Rights Reserved.